Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 425 | 37% |
| 2020 | 4 | 368 | 40% |
| 2021 | 1 | 339 | 43% |
| 2022 | 2 | 304 | 46% |
| 2023 | 3 | 270 | 50% |
| 2024 | 3 | 302 | 54% |
| 2025 from claims | – | 228 184–267 | 54% |
| 2026 forecast | – | 231 181–290 | 54% |
| 2027 forecast | – | 231 171–305 | 55% |
| 2028 forecast | – | 231 164–319 | 56% |
| 2029 forecast | – | 231 157–331 | 57% |
| 2030 forecast | – | 231 151–343 | 57% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Washington; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 6 | 979−4.9%/yr | −4.9%/yr | 0.3 | 0% | 1,400 in 2030+6.1%/yr |
| Arizona | 3 | 322−6.9%/yr | −6.9%/yr | 0.4 | 0% | 370 in 2030+2.5%/yr |
| Colorado | 0 | 174−6.8%/yr | −6.8%/yr | 0.4 | 0% | 200 in 2030+2.7%/yr |
| Oregon | 0 | 169−9.9%/yr | −9.9%/yr | 0.4 | 0% | 170 in 2030−0.3%/yr |
| Nevada | 0 | 117−8%/yr | −8%/yr | 0.4 | 0% | 100 in 2030−2.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 30 | 2,051−12%/yr | −12%/yr | 2.80.5× | 19% | 1,780 in 2030−2.4%/yr |
| Peripheral arterial intervention | 15 | 2,037−9%/yr | −9%/yr | 2.50.5× | 14% | 2,490 in 2030+3.4%/yr |
| Superficial venous ablation | 7 | 779−7.1%/yr | −7.1%/yr | 1.00.2× | 83% | 860 in 2030+1.7%/yr |
| Carotid revascularization | 15 | 658−6.5%/yr | −6.5%/yr | 0.81.0× | 0% | 680 in 2030+0.6%/yr |
| Thrombectomy, IVC filters & venous stents | 3 | 587+1.3%/yr | +1.3%/yr | 0.80.6× | 0% | 1,070 in 2030+11%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
W L Gore & Associates leads with 51% of company spending on these surgeons in 2025, +44 pts on 2024.
In 2025, 5 companies reported engagement with Washington’s surgeons worth $59K in consulting, speaking, meals and travel tied to these products, about $20K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.